Search results for Sarilumab

Sarilumab Biosimilar – Anti-IL-6R mAb – Research Grade, ProteoGenix, PX-TA1028

Description of Sarilumab Biosimilar - Anti-IL-6R mAb - Research Grade General information on Sarilumab Therapeutic Antibody The Sarilumab antibody is a fully human IgG1 kappa monoclonal protein targeting the human interleukin 6 receptor (IL-6R). It has been generated using the VelocImmune® platform by Regeneron Pharmaceuticals Inc. which consists of immunizing engineered mice modified to produce fully human antibodies instead of murine immunoglobulins. Sarilumab was granted approval by the Food and Drug Administration (FDA) in 2017 for the treatment of rheumatoid arthritis (RA), an autoimmune condition. RA is a long-term condition affecting hands, feet, and wrists often causing tiredness and weight loss. Sarilumab and Tocilizumab (a humanized monoclonal antibody) share the same molecular target and mechanism of action. By competitively binding the IL-6R, both antibodies are known to disrupt the pro-inflammatory response caused by the interleukin 6 (IL-9) molecule, a small soluble glycoprotein known to be overexpressed in multiple inflammatory pathologies such as the cytokine release syndrome or “cytokine storm.” Both antibodies have proved their effectiveness as monoclonal antibody therapies in vitro and the clinic. However, recent studies have shown that Sarilumab’s in vitro binding affinity is 15-22-fold higher than that of Tocilizumab. The improved affinity also translated into a better clinical efficiency suggesting that Sarilumab is capable of effectively blocking the IL-6R with a lower dose and dosage frequency than the ones recurrently necessary in Tocilizumab-based therapies. Consequently, Sarilumab may have an overall lower cost than its humanized counterpart for the treatment of multiple diseases. The evaluation of Sarilumab as a COVID-19 treatment is currently under regulatory revision. Prior studies with this therapeutic antibody showed a marked improvement in patients in intensive care (over 89% of patients experienced a significant improvement after receiving the antibody intravenously). However, further studies are necessary to access the efficiency and safety of the fully human therapeutic antibody for blocking IL-6R in COVID-19 patients and arrest the onset of the acute respiratory distress syndrome (ARDS) shown to contribute to significant lung damage in the most severe cases of the disease. This product is for research use only.

Sarilumab, Abbexa, abx831234

Sarilumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL6R/CD126, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Sarilumab is a fully human anti-IL-6R monoclonal IgG1 antibody that binds to both membrane bound and soluble interleukin 6 (IL-6) receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6 1. Sarilumab was developped by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe Rheumatoid Arthritis (RA) in combination with methotrexate 4. RA is a chronic inflammatory disease characterized by polyarthritis and its treatment has been challenged by the different response in every patient 3. Subcutaneous administration of Sarilumab has been shown to decrease acute-phase reactant levels and improve in clinical RA symptoms 2.

Sarilumab Antibody, Abbexa, abx376590

Sarilumab Antibody is a rabbit polyclonal antibody for the detection of Sarilumab.

Anti-Sarilumab Polyclonal Antibody, AntibodySystem, PAC36901

Sarilumab Biosimilar - Research Grade, ichor.bio, ICH5107

Detects human IL-6R

Anti-Sarilumab Neutralizing Antibody ELISA kit, ProteoGenix, KPTX309

Description of Anti-Sarilumab Neutralizing Antibody ELISA kit Introduction The Anti-Sarilumab Neutralizing Antibody ELISA kit is a highly sensitive and specific assay designed for the detection and quantification of neutralizing antibodies against Sarilumab, a therapeutic target used in the treatment of inflammatory diseases such as rheumatoid arthritis (RA). This kit is widely used in both research and clinical settings to evaluate the efficacy and immunogenicity of Sarilumab treatment. Structure of Sarilumab Sarilumab is a fully human monoclonal antibody that specifically targets the interleukin-6 receptor (IL-6R). It is composed of two identical heavy chains and two identical light chains, each containing variable and constant regions. The variable regions of Sarilumab bind to the IL-6R, blocking its interaction with IL-6 and preventing downstream signaling pathways that contribute to inflammation. Activity of Sarilumab Sarilumab is a potent inhibitor of IL-6 signaling and has been shown to effectively reduce the symptoms and progression of RA in clinical trials. IL-6 is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of RA, as well as other autoimmune and inflammatory diseases. By blocking the IL-6R, Sarilumab reduces the activation of immune cells and the production of inflammatory mediators, leading to improved clinical outcomes for patients. Application of Anti-Sarilumab Neutralizing Antibody ELISA kit The Anti-Sarilumab Neutralizing Antibody ELISA kit is used to measure the presence and levels of neutralizing antibodies against Sarilumab in patient samples. This is important in assessing the efficacy and potential immunogenicity of Sarilumab treatment in both research and clinical settings. Research Use In research settings, the Anti-Sarilumab Neutralizing Antibody ELISA kit is used to evaluate the immunogenicity of Sarilumab in preclinical and clinical studies. It allows researchers to monitor the development of neutralizing antibodies in response to Sarilumab treatment and assess their potential impact on the efficacy and safety of the drug. Therapeutic Target The Anti-Sarilumab Neutralizing Antibody ELISA kit is also a valuable tool for identifying patients who may be at risk of developing neutralizing antibodies against Sarilumab. This information can help clinicians make informed decisions about the most appropriate treatment options for individual patients, as well as monitor their response to therapy. Assay Procedure The Anti-Sarilumab Neutralizing Antibody ELISA kit utilizes a competitive ELISA format to detect and quantify the presence of neutralizing antibodies against Sarilumab. The assay involves incubating patient samples with a fixed amount of Sarilumab and a labeled form of the drug. Any neutralizing antibodies present in the sample will bind to the Sarilumab, preventing its binding to the labeled form. The amount of labeled Sarilumab remaining in the sample is then measured and compared to a standard curve, allowing for the quantification of neutralizing antibodies. Benefits of Anti-Sarilumab Neutralizing Antibody ELISA kit The Anti-Sarilumab Neutralizing Antibody ELISA kit offers several advantages over other methods of detecting neutralizing antibodies against Sarilumab. It is highly sensitive, with a lower limit of detection of 0.1 ng/mL, and has a wide dynamic range of 0.1-100 ng/mL. It is also specific for Sarilumab, with no cross-reactivity to other therapeutic antibodies. Furthermore, this assay can be easily performed in any laboratory with standard ELISA equipment, making it a convenient and cost-effective option for researchers and clinicians. Conclusion The Anti-Sarilumab Neutralizing Antibody ELISA kit is a valuable tool for assessing the immunogenicity and efficacy of Sarilumab treatment in patients with RA and other inflammatory diseases. Its high